Impact of statins on mortality and disease progression in patients with Alzheimer’s disease: a nationwide cohort study

IF 6.7 1区医学 Q1 ENDOCRINOLOGY & METABOLISM

Frontiers in Neuroendocrinology Pub Date : 2025-10-01 DOI:10.1016/j.yfrne.2025.101218

Yoonjung Park , Hyun Woo Lee , Byoung Seok Ye , Seungyeon Kim , Yun Mi Yu

{"title":"Impact of statins on mortality and disease progression in patients with Alzheimer’s disease: a nationwide cohort study","authors":"Yoonjung Park , Hyun Woo Lee , Byoung Seok Ye , Seungyeon Kim , Yun Mi Yu","doi":"10.1016/j.yfrne.2025.101218","DOIUrl":null,"url":null,"abstract":"<div><div>Recent studies have investigated the neuroprotective potential of statins; however, clinical evidence for delayed Alzheimer’s disease (AD) progression remains scarce. This study investigated the association between statin use and AD progression, as assessed by mortality and memantine initiation. Using data from the Korean National Health Insurance Database, we retrospectively analyzed a cohort of patients aged 60–79 years diagnosed with AD in 2010. After 1:1 propensity score matching, 7,086 patients were included in the study. Statin use was associated with a reduced risk of mortality (HR, 0.84; 95 % CI = 0.74–0.97), notably among previous users (HR, 0.82; 95 % CI = 0.70–0.97), while no delay in memantine initiation was observed (HR, 1.04; 95 % CI = 0.86–1.26). Results were consistent across sensitivity analyses, with no significant interactions by age, sex, or comorbidities. These findings suggest a potential mortality benefit of statins in AD, warranting further investigation into their therapeutic role.</div></div>","PeriodicalId":12469,"journal":{"name":"Frontiers in Neuroendocrinology","volume":"79 ","pages":"Article 101218"},"PeriodicalIF":6.7000,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Frontiers in Neuroendocrinology","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0091302225000445","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"ENDOCRINOLOGY & METABOLISM","Score":null,"Total":0}

引用次数: 0

Abstract

Recent studies have investigated the neuroprotective potential of statins; however, clinical evidence for delayed Alzheimer’s disease (AD) progression remains scarce. This study investigated the association between statin use and AD progression, as assessed by mortality and memantine initiation. Using data from the Korean National Health Insurance Database, we retrospectively analyzed a cohort of patients aged 60–79 years diagnosed with AD in 2010. After 1:1 propensity score matching, 7,086 patients were included in the study. Statin use was associated with a reduced risk of mortality (HR, 0.84; 95 % CI = 0.74–0.97), notably among previous users (HR, 0.82; 95 % CI = 0.70–0.97), while no delay in memantine initiation was observed (HR, 1.04; 95 % CI = 0.86–1.26). Results were consistent across sensitivity analyses, with no significant interactions by age, sex, or comorbidities. These findings suggest a potential mortality benefit of statins in AD, warranting further investigation into their therapeutic role.

查看原文本刊更多论文

他汀类药物对阿尔茨海默病患者死亡率和疾病进展的影响：一项全国性队列研究

最近的研究调查了他汀类药物的神经保护潜力；然而，迟发性阿尔茨海默病（AD）进展的临床证据仍然很少。本研究调查了他汀类药物使用与AD进展之间的关系，通过死亡率和美金刚启动来评估。使用韩国国民健康保险数据库的数据，我们回顾性分析了2010年诊断为AD的年龄在60-79 岁的患者队列。经1:1倾向评分匹配后，7086例患者纳入研究。他汀类药物的使用与死亡风险降低相关（HR, 0.84; 95 % CI = 0.74-0.97），特别是在以前的使用者中（HR, 0.82; 95 % CI = 0.70-0.97），而未观察到美金刚开始治疗的延迟（HR, 1.04; 95 % CI = 0.86-1.26）。敏感性分析的结果是一致的，年龄、性别或合并症之间没有显著的相互作用。这些发现表明他汀类药物对阿尔茨海默病有潜在的死亡率益处，值得进一步研究其治疗作用。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Frontiers in Neuroendocrinology 医学-内分泌学与代谢

CiteScore

13.30

自引率

6.80%

发文量

审稿时长

68 days

期刊介绍： Frontiers in Neuroendocrinology (FIN) publishes a wide range of informative articles including comprehensive reviews, systematic reviews, opinion pieces, and meta-analyses. While the majority of reviews are invited, we also embrace unsolicited reviews and meta-analyses, as well as proposals for thematic special issues, provided they meet our rigorous quality standards. In addition, we encourage authors to submit commentaries that concisely present fresh ideas or offer further analysis to delve deeper into the implications of an article published in our journal.